Laetitia E. Lamberts

Groningen, GR, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

89Zr-Lumretuzumab PET Imaging before and during HER3 Antibody Lumretuzumab Treatment in Patients with Solid Tumors.

89Zr-Lumretuzumab PET Imaging before and during HER3 Antibody Lumretuzumab Treatment in Patients with Solid Tumors.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: February 03, 2017

Threshold Analysis and Biodistribution of Fluorescently Labeled Bevacizumab in Human Breast Cancer.

Threshold Analysis and Biodistribution of Fluorescently Labeled Bevacizumab in Human Breast Cancer.

Journal: Cancer research

Published: July 21, 2016

Tumor-Specific Uptake of Fluorescent Bevacizumab-IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study.

Tumor-Specific Uptake of Fluorescent Bevacizumab-IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: February 20, 2016

Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial.

Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: October 29, 2015

Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer.

Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer.

Journal: Molecular cancer therapeutics

Published: August 19, 2015

Imaging the distribution of an antibody-drug conjugate constituent targeting mesothelin with ⁸⁹Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts.

Imaging the distribution of an antibody-drug conjugate constituent targeting mesothelin with ⁸⁹Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts.

Journal: Oncotarget

Published: August 03, 2015

ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody-Drug Conjugate Treatment.

ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody-Drug Conjugate Treatment.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: May 29, 2015

Functional genomic mRNA profiling of a large cancer data base demonstrates mesothelin overexpression in a broad range of tumor types.

Functional genomic mRNA profiling of a large cancer data base demonstrates mesothelin overexpression in a broad range of tumor types.

Journal: Oncotarget

Published: March 20, 2015

Antibody positron emission tomography imaging in anticancer drug development.

Antibody positron emission tomography imaging in anticancer drug development.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 18, 2015

HER3, serious partner in crime: therapeutic approaches and potential biomarkers for effect of HER3-targeting.

HER3, serious partner in crime: therapeutic approaches and potential biomarkers for effect of HER3-targeting.

Journal: Pharmacology & therapeutics

Published: September 27, 2013

Molecular imaging for monitoring treatment response in breast cancer patients.

Molecular imaging for monitoring treatment response in breast cancer patients.

Journal: European journal of pharmacology

Published: July 04, 2012

IBD is associated with an increase in carcinoma in PSC irrespective of the presence of dominant bile duct stenosis.

IBD is associated with an increase in carcinoma in PSC irrespective of the presence of dominant bile duct stenosis.

Journal: Journal of hepatology

Published: January 02, 2012

Showing 1-12 of 12

Last Updated: 09/26/2026